ClinicalTrials.gov
Cure8 trial brief
Atorvastatin in Patients With Ulcerative Colitis
Research and clinical trials
Mesalamine
Corticosteroids
Steroids
Aminosalicylates
Phase 2 clinical trial
Adult patients
Clinicians
Why This Matters
Researchers tested whether adding a high-dose statin (atorvastatin 80 mg) to mesalamine improves quality of life for people with ulcerative colitis. If beneficial, a commonly used, inexpensive drug could offer a new adjunct approach for some patients not on immunosuppressives or biologics.
Who Should Pay Attention
Adults with ulcerative colitis (not on steroids, immunosuppressives, or biologics), gastroenterologists, IBD researchers, and clinicians interested in repurposing cardiovascular drugs for inflammatory disease.
Study Snapshot
Story typeClinical Reference
Trial phasePhase 2
Enrollment50 participants
Study statusCompleted
Source depthTrial registry record
What To Know
A Phase 2 interventional trial (completed) registered at ClinicalTrials.gov tested adding atorvastatin 80 mg daily to standard mesalamine (1 g three times daily) in adults with ulcerative colitis.
The trial planned about 50 participants and compared health-related quality of life (SF-36) at 6 months between the atorvastatin-plus-mesalamine group and a mesalamine-only control group. The registry entry highlights rationale: statins like atorvastatin have anti-inflammatory and immunomodulatory effects beyond cholesterol lowering.
Key exclusions included severe UC, current systemic or rectal steroids, immunosuppressives, biologics, significant liver/kidney dysfunction, pregnancy, and breastfeeding. This record reports study design and registered outcomes (HRQL by SF-36) but does not provide results or efficacy/safety findings in the provided text.
For outcome data or safety information, look for a results posting on ClinicalTrials.gov, a peer-reviewed publication from the study investigators, or contact the study site listed (Faculty of Medicine, Mansoura University).
Keep In Mind
This is a trial registry record (Phase 2, completed) describing study design and planned outcomes; the supplied text does not include trial results. Statins can affect liver enzymes and are contraindicated in significant liver disease, which aligns with the trial's exclusion criteria. Do not interpret this entry as evidence of benefit without seeing published outcome data.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorTanta University
Trial IDNCT05561062
Study typeInterventional
Trial phasePhase 2
Enrollment50 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedOct 30, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Phosphodiesterase Inhibitors, Pentoxifylline, as Adjunctive Therapy in Patients With Ulcerative Colitis.
Patients with ulcerative colitis and their clinicians may be interested because the study tests whether adding pentoxifylline to standard mesalamine improves disease activity measured by the Mayo Score over 6 months.
Conventional vs Biologic Therapy in Pediatric IBD
Pediatric-onset IBD can behave differently than adult-onset disease. Comparing conventional versus biologic approaches in children may help clarify relative effectiveness, safety, and impacts on growth and steroid...
A Trial of HRS-7085 Tablets in Patients With Moderate to Severe Active Ulcerative Colitis
A new oral investigational drug (HRS-7085) is entering early human testing for moderate-to-severe ulcerative colitis. People with UC who have not benefited from approved therapies may be interested in trial options and...